ruthenium has been researched along with 2,6-bis(benzimidazol-2-yl)pyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baitalik, S; Bhaumik, C; Das, S; Dutta, S; Saha, D | 1 |
| Cao, W; Chen, T; Fan, C; Li, L; Zheng, W | 1 |
2 other study(ies) available for ruthenium and 2,6-bis(benzimidazol-2-yl)pyridine
| Article | Year |
|---|---|
Synthesis, characterization, photophysical, and anion-binding studies of luminescent heteroleptic bis-tridentate ruthenium(II) complexes based on 2,6-bis(benzimidazole-2-yl)pyridine and 4'-substituted 2,2':6',2'' terpyridine derivatives.
Topics: Anions; Benzimidazoles; Binding Sites; Luminescence; Molecular Structure; Organometallic Compounds; Photochemistry; Pyridines; Ruthenium; Stereoisomerism | 2010 |
Ruthenium complexes containing 2,6-bis(benzimidazolyl)pyridine derivatives induce cancer cell apoptosis by triggering DNA damage-mediated p53 phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line, Tumor; DNA Damage; Histones; Humans; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; Ruthenium; Tumor Suppressor Protein p53 | 2012 |